ETFs and Mutual Funds: Why not both?
Shire Pharmaceuticals SHPGY recently announced that the FDA approved its Hunter syndrome therapy, Elaprase, for marketing. We're slightly raising our fair value estimate to account for this new addition to Shire's product portfolio. Shire received rights
Read the rest of this article on Morningstar Articles